Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02322788 | Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3 | PHASE3 | COMPLETED | 95 | — | — | Mar 1, 2015 | Nov 1, 2015 | Jan 13, 2017 | 4 | Canada, Netherlands +1 |
| Arm | Type | Description |
|---|---|---|
| Bricanyl Turbuhaler M2, Active | ACTIVE_COMPARATOR | Terbutaline sulphate powder for inhalation, 0.5 mg terbutaline per inhalation |
| Bricanyl Turbuhaler M3, Active | ACTIVE_COMPARATOR | Terbutaline sulphate powder for inhalation, 0.4 mg terbutaline per inhalation |
| Turbuhaler M2, Placebo | PLACEBO_COMPARATOR | Placebo powder for inhalation |
| Turbuhaler M3, Placebo | PLACEBO_COMPARATOR | Placebo powder for inhalation |
| Name | Type | Description |
|---|---|---|
| Terbutaline sulphate | DRUG | Bricanyl Turbuhaler M2 |
| Placebo for terbutaline sulphate | DRUG | Placebo Turbuhaler M2 |
Inclusion Criteria: - Female and male aged 18 and 65 years. * At least 6 months of documented clinical diagnosis of asthma as defined by GINA 2012 or American Thoracic Society (Expert Panel Report 3 2007) prior to visit 1 * Stable asthmatics on SABA alone, on low dose ICS (200-400 µg budesonide cor...